No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML

Abstract

This study provides Class III evidence that for patients with NTZ-PML, PLEX does not improve survival. The study lacks the statistical precision to exclude an important benefit or harm of PLEX.